1. Market Research
  2. > Biotechnology Market Trends
  3. > Biopharmaceutical

Biopharmaceutical Sector: Get Market Research and Figures

  • Currently 4/5 Stars.
  • 1
  • 2
  • 3
  • 4
  • 5
10 votes

Global Biopharmaceutical Industry

The global biopharmaceutical industry (a part of the biotechnology market) is currently worth over $145 billion, according to research conducted by BioPlan Associates. The industry should exceed $167 billion in 2015, says IMARC. 

Biopharmaceuticals are used in the prevention and treatment of disease, and there are over 300 approved biopharmaceuticals on the market, with many in clinical development yet to come. The market has benefited from the need for pharmaceutical manufacturers to boost output, but it has a high risk factor, with only three out of 10 drugs that pass to the clinical phase receiving market clearance.

Cost containment and biosimilar entry in developed markets continue to see slow growth, but the market should expand thanks to biopharmaceutical capacity to outperform traditional small molecule drugs. Over the coming five-year period, factors such as development of emerging markets and a rich late-stage pipeline are expected to fuel growth.

Key Market Segments

The world biosimilar market is expected to record yearly growth in excess of 50% between 2010 and 2015, reports RNCOS. Market growth is being driven by factors such as costly drugs, high pharmaceutical expenditure and a global aging population. Market expansion will be further fuelled by expiring patents and the increasing cost of drugs. Sandoz is the leading company operating in the global biosimilars market, recording the highest sales. Teva and Hospira are developing a biosimilar product range.

The global enzyme market is expected to exceed $7.5 billion in 2015, reports Freedonia, and it should surpass yearly growth of 5%. The fastest rate of growth will be recorded in smaller markets such as the Africa/Middle East region, and Central and South America. Asia-Pacific is expected to record strong growth, while the EU and North America are forecast to record below-average growth.

The global protein therapeutics market is forecast to see yearly growth of 13% between 2012 and 2014, reports RNCOS. Increased investment and the introduction of new protein therapeutics will fuel market  expansion. Protein therapeutics have been recording a high rate of growth in recent years, vital to the treatment of many diseases. Protein therapeutics are particularly efficient due to their targeted approach, which allows the treatment of disease with little or no negative impact on healthy organs. Protein therapies are necessary in a healthcare landscape, witnessing rapidly rising rates of chronic illnesses like cardiovascular diseases, diabetes and cancer.

The cancer monoclonal antibodies market is expected to grow at a yearly rate in excess of 5% between 2012 and 2015, according to RNCOS. Cancer monoclonal antibodies are used to treat tumors with a high degree of specification. The market is driven by increasing prevalence of cancer and the need for more innovation research. The industry is witnessing rising consolidation.

Read more »

Share

You might be interested in these related markets:

24/7 Customer Support

Talk to Sam

+33 9 70 44 05 99

1-10 of about 8 800 reports

Global Biopharmaceutical Industry

  • April 2016
    8 pages
  • Biopharmaceutic...  

    Biopharmaceutic...  

View report >

Biopharmaceutical Industry in the US

  • June 2016
    11 pages
  • Biopharmaceutic...  

  • United States  

View report >

Biopharmaceutical Industry in Europe

  • January 2016
    5 pages
  • Biopharmaceutic...  

    Bioprocessing  

    Cell Culture  

  • Europe  

View report >

Biopharmaceutical Industry in the US and Asia

  • April 2015
    9 pages
  • United States  

    Asia  

View report >

Biopharmaceutical Industry in Japan

  • June 2016
    8 pages
  • Biopharmaceutic...  

  • Japan  

View report >

Biopharmaceutical Industry in France

  • January 2016
    11 pages
  • Biopharmaceutic...  

    Protein  

    Enzyme  

  • France  

View report >

Biopharmaceutical Industry in Germany

  • March 2016
    7 pages
  • Biopharmaceutic...  

  • Germany  

View report >

Biopharmaceutical Industry in the US and Italy

  • January 2015
    12 pages
  • Biopharmaceutic...  

  • United States  

    Italy  

View report >

Biopharmaceutical Industry in the UK

  • November 2015
    9 pages
  • Biopharmaceutic...  

  • United Kingdom  

View report >

Biopharmaceutical Forecast Statistics in Canada

  • November 2015
    19 pages
  • Therapy  

  • Canada  

View report >

Search in Biopharmaceutical Industry (About 8 800 reports)
Parent industry: Biotechnology
Related industries: Biological Therapy, Biomaterial, Genetically Modified Organism, Genomics

About 3 200 reports

Purchase Reports From Reputable Market Research Publishers
(From € 79 - € 34 023)

Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H1 2016

Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H1 2016

  • € 34 023
  • Company report
  • June 2016
  • by Global Markets Direct

Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H1 2016’, provides an overview of the Kidney Cance ...

Hospital Acquired Methicillin-resistant Staphylococcus ...

June 2016 € 34 023

Poliomyelitis - Pipeline Review, H1 2016

June 2016 € 34 023

Sangamo Biosciences, Inc. - Product Pipeline Review - 2 ...

June 2016 € 34 023

Pituitary Acth Hypersecretion (cushing Disease) - Pipel ...

June 2016 € 34 023

Mucopolysaccharidosis Iii (mps Iii) (sanfilippo Syndrom ...

June 2016 € 34 023

Toxoplasmosis - Pipeline Review, H1 2016

June 2016 € 34 023

Nanotherapeutics, Inc. - Product Pipeline Review - 2016

June 2016 € 34 023

Type 1 Diabetes (juvenile Diabetes) - Pipeline Review, ...

June 2016 € 34 023

Streptococcal Pneumonia - Pipeline Review, H1 2016

June 2016 € 34 023

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.